Related Experiment Video
Updated: Jan 22, 2026

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
Published on: May 21, 2017
Prognostically Significant Myocardial Injury in Patients Undergoing Transcatheter Aortic Valve Replacement
Vikram Sharma1, Tanujit Dey2, Kesavan Sankaramangalam3
11 Department of Hospital Medicine The Cleveland Clinic Cleveland OH.
Insights
Troponin T elevation of at least 3x the upper limit of normal after transcatheter aortic valve replacement (TAVR) predicts long-term mortality. This myocardial injury is not linked to coronary artery disease but other TAVR complications.
Area of Science:
- Cardiology
- Cardiovascular Surgery
- Biomarkers
Background:
- Troponin elevation is common after transcatheter aortic valve replacement (TAVR).
- Prognostic significance of troponin elevation post-TAVR remains unclear.
- Coronary artery disease (CAD) association with myocardial injury needs further investigation.
Purpose of the Study:
- Determine the optimal troponin T cutoff for predicting long-term mortality post-TAVR.
- Investigate the relationship between CAD and prognostically significant myocardial injury in TAVR patients.
Main Methods:
- Retrospective, observational, single-center study.
- Included 510 patients undergoing TAVR between 2010-2015.
- Utilized ROC analysis and multivariate analyses for troponin T cutoffs and mortality correlation.
Main Results:
- Troponin T elevation ≥3× upper limit of normal best predicted long-term mortality (AUC 0.57), excluding transapical TAVR.
- Elevated troponin T (≥3× ULN) was significantly associated with increased long-term mortality (HR 1.57, P=0.03).
- Unrevascularized CAD and left main disease correlated with mortality but not with significant myocardial injury.
Conclusions:
- Troponin T elevation ≥3× upper limit of normal is a significant predictor of long-term mortality post-TAVR (excluding transapical approach).
- Prognostically significant myocardial injury post-TAVR is not primarily due to severe or unrevascularized CAD.
- Other post-TAVR complications likely contribute to significant myocardial injury and mortality.
Abstract:
Background Troponin elevation occurs commonly in the setting of transcatheter aortic valve replacement (TAVR). There is a lack of information on the extent of troponin elevation post TAVR that is prognostically significant. We assessed the optimal cutoff for post-TAVR troponin T elevation that correlates with long-term mortality. We also examined the relationship between coronary artery disease (CAD) and prognostically significant myocardial injury in TAVR. Methods and Results This is a retrospective, observational single-center study involving patients who underwent TAVR at Cleveland Clinic between 2010 and 2015. Five hundred ten patients were included (mean follow-up of 2.6±1.3 years). Receiver operating characteristic analysis showed that troponin T elevation ≥3× upper limit of normal was the best predictor of long-term mortality post TAVR with area under the curve of 0.57, with transapical TAVR patients excluded. Multivariate analyses confirmed that troponin T elevation ≥3× upper limit of normal was significantly associated with increased long-term mortality post TAVR (hazard ratio 1.57, CI 1.04-2.38, P=0.03). The most common causes for the presence of unrevascularized CAD included the presence of chronic total occlusion in the native/graft vessels (49.7%) and diffuse/complex CAD unsuitable for PCI (24.6%). The presence of unrevascularized CAD and significant left main disease correlated with increased mortality, but not with the presence of prognostically significant myocardial injury. Conclusions Troponin T elevation of ≥3× upper limit of normal is associated with increased long-term mortality after TAVR, except for the transapical approach. This prognostically significant myocardial injury does not appear to be secondary to severe CAD/unrevascularized CAD or left main disease, but rather is associated with other factors such as post-TAVR complications.
Related Concept Videos
Heart Valves
The AV valves prevent the backflow of blood from the ventricles to the atria during ventricular contraction. These valves function with the assistance of the chordae tendineae and papillary muscles. When the ventricles are relaxed, the chordae tendineae are slack, allowing blood to flow from the atria into the...
Continuous Renal Replacement Therapy
Mitral Valve Prolapse I: Introduction
Aortic Regurgitation I: Introduction
Mitral Valve Prolapse II: Assessment and Management
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

